"PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022" Published

From: Fast Market Research, Inc.
Published: Wed Jul 10 2013


GlobalData has released its new Country report, "PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022". Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi's Menactra and Novartis' Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

Full Report Details at
- http://www.fastmr.com/prod/642941_pharmapoint_meningococcal_vaccines_italy_drug.aspx?afid=302

Total sales in this segment of the market will decline slightly due to a population decrease in the targeted age group of 12-24 months of age. GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotech's Meningitec, Novartis' Menjugate, and Baxter's NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Italy and therefore is not expected to change drastically during the forecast period.

Scope

* Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Italy from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting Italy Meningococcal Vaccines market.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in Italy

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »